Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults
A Multi-center, Phase II, Single-arm Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults
調査の概要
詳細な説明
研究の種類
入学 (予想される)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Jiangsu
-
Suzhou、Jiangsu、中国、215000
- The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male or female, Age (years) >= 18;
Patients newly diagnosed or previously treated with MDS/MPNs (CMML, MDS/MPN-U, aCML) according to 2016 WHO diagnostic criteria:
Initial diagnosis: CMML: CPSS-mol intermediate risk 2 and above; aCML; MDS/MPN-U.
Previous treatment: HMA treatment failed.
- Eastern Cooperative Oncology Group (ECOG) Performance status of 0,1, 2 ;
- Liver function: Total bilirubin ≤3 upper limit of normal (ULN); aspartate aminotransferase (AST) ≤3 ULN; alanine aminotransferase (ALT)≤3 ULN;
- Renal function#Ccr ≥30 ml/min;
- Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.
Exclusion Criteria:
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Subjects who had previously been treated with Venetoclax
- Subjects who are known to be allergic to ingredients of the study drug or their analogues
- HIV infection
- HBV-DNA or HCV-RNA positive
- Subjects with grade 2 or above cardiac failure and those considered unsuitable for inclusion by the investigator
- Subjects who are pregnant or breastfeeding
- Subjects reject to participate in the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Treatment regime
On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days.
Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
|
On day 1 of each cycle, decitabine 75 mg/m2 will be given subcutaneously, and will continue for 5 days.
Simultaneously the patient will start out with Venetoclax 100mg and progress to 400mg until the 14 day cycle is finished.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Overall Response Rate (ORR)
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
ORR (equals the rates of complete remission [CR]+partial remission [PR]+complete cytogenetic remission [CCyR]+marrow response [MR[+clinical benefit [CB] )of venetoclax in combination with azacitidine.
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Complete remission rate
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
Complete remission rate of bone marrow morphology
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
Presence of all marrow criteria necessary for CR without normalization of peripheral blood indices as presented above.
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
Hematology improvement (HI) rate
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
Percentages of participants with HI (erythroid/platelet/neutrophil responses)
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
Complete cytogenetic remission rate
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
Resolution of previously present chromosomal abnormality (known to be associated with myelodysplastic, syndrome myeloproliferative neoplasms, or MDS/MPN), as seen on classic karyotyping with minimal of 20 metaphases or FISH.
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
Incidence of severe infection (≥grade 3 )
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
Assessed using CTCAE 5
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
Spleen response rate
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
Either a minimum 50% reduction in palpable splenomegaly of a spleen that is at least 10 cm at baseline or a spleen that is palpable at more than 5 cm at baseline becomes not palpable.
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
Symptom response rate
時間枠:Study start date to study end date, or death, whichever comes first, up to 4 years
|
Improvement in symptoms as noted by decrease of ≥50% as per the MPN-SAF TSS scoring<20 were not considered eligible for measuring clinical benefit.
|
Study start date to study end date, or death, whichever comes first, up to 4 years
|
協力者と研究者
捜査官
- 主任研究者:Suning Chen, Professor、The First Affiliated Hospital of Soochow University
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。